Literature DB >> 16211715

Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model.

Chun-Wing Chan1, James R Carpenter, Cristina Rigamonti, Fulya Gunsar, Andrew K Burroughs.   

Abstract

OBJECTIVE: Current prognostic models in primary biliary cirrhosis (PBC) have low precision, partly due to the restricted inclusion criteria of some cohorts used for modelling but also because of the prolonged natural course of the disease. It is hypothesized that better precision could be achieved with a staged model, using ascites or peripheral oedema as a new starting-point for prediction.
MATERIAL AND METHODS: The study was based on an established database of 289 consecutive patients, followed between 1977 and 1998. Stepwise Cox regression was used to construct a staged model based on 143 patients who first developed ascites (n=111) or peripheral oedema (n=32) at entry or during subsequent follow-up. The model was compared with published models using graphical methods and receiver operating characteristics (ROCs).
RESULTS: Mean time from clinical diagnosis of ascites or peripheral oedema to death was 3.1 years. The following variables had independent prognostic significance: log10(bilirubin) (p<0.001), albumin (p<0.001), age (p<0.001) and history of encephalopathy (p<0.001). Goodness of fit showed that the survival probabilities predicted by the Ascites Stage Model fitted well with the observed data. The Ascites Stage Model (ROC 0.8324 (SE 0.0348)) was a better predictor of survival than the Mayo long-term model (ROC 0.7833 (SE 0.0397)), the Mayo Repeated Patient Visits Model (ROC 0.7779 (SE 0.0399)) and the Royal Free PBC Prognostic Model (ROC 0.7785 (SE 0.0396)).
CONCLUSIONS: The Ascites Stage Model gives a better survival estimate for PBC patients once they have developed ascites or peripheral oedema compared with the current models, and demonstrates an advantage of staged models in diseases with a prolonged natural history.

Entities:  

Mesh:

Year:  2005        PMID: 16211715     DOI: 10.1080/00365520510023215

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

1.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

Review 2.  Diagnosis and treatment of primary biliary cholangitis.

Authors:  Alena Laschtowitz; Rozanne C de Veer; Adriaan J Van der Meer; Christoph Schramm
Journal:  United European Gastroenterol J       Date:  2020-04-16       Impact factor: 4.623

3.  Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Authors:  Maren H Harms; Willem J Lammers; Douglas Thorburn; Christophe Corpechot; Pietro Invernizzi; Harry L A Janssen; Pier M Battezzati; Frederik Nevens; Keith D Lindor; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; George N Dalekos; Tony Bruns; Albert Parés; Andrew L Mason; Xavier Verhelst; Kris V Kowdley; Jorn C Goet; Gideon M Hirschfield; Bettina E Hansen; Henk R van Buuren
Journal:  Am J Gastroenterol       Date:  2017-12-12       Impact factor: 10.864

4.  Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.

Authors:  V Papastergiou; E A Tsochatzis; M Rodriguez-Peralvarez; M Rodriquez-Peralvarez; E Thalassinos; G Pieri; P Manousou; G Germani; C Rigamonti; V Arvaniti; S Karatapanis; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2013-10-05       Impact factor: 8.171

5.  Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy.

Authors:  Emmanuel A Tsochatzis; Maurille Feudjo; Cristina Rigamonti; Jiannis Vlachogiannakos; James R Carpenter; Andrew K Burroughs
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.